SEARCH BY
| Category | Company |
|---|---|
| Founded | 1876 |
| Sector | Life Science |
| Employees | 43,000 |
| Revenue | 45.0B USD (2024) |
Lilly discovers, develops, manufactures, and markets products in two business segments—human pharmaceutical products and animal health products. The mission of its human pharmaceutical business is to make medicines that help people live longer, healthier, more active lives. Most of the products Lilly sells were discovered or developed by its own scientists, and the Company's success depends to a great extent on its ability to continue to discover, develop, and bring to market innovative new medicines. The company's animal health business, operating through its Elanco division, develops, manufactures, and markets products for both food animals and companion animals. The company manufactures and distributes its products through facilities in the US, Puerto Rico, and 11 other countries. Lilly was founded in 1876 and is based in Indianapolis, Indiana.
| DEAL STATS | # |
|---|---|
| Overall | 38 of 38 |
| Sector: Life Science M&A | 31 of 31 |
| Type: Add-on Acquisition M&A Deals | 30 of 30 |
| State: California M&A | 13 of 13 |
| Country: United States M&A | 33 of 33 |
| Year: 2025 M&A | 4 of 4 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2025-06-17 |
Verve Therapeutics
Cambridge, Massachusetts, United States Verve Therapeutics is a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. Verve Therapeutics was founded in 2018 and is based in Cambridge, Massachusetts. |
Buy | $1.3B |
